tldrdailynews.com logo

Nuvalent Raises $300M in Public Stock Offering

1 min read
Source: Endpoints News
Nuvalent Raises $300M in Public Stock Offering
Photo: Endpoints News
TL;DR

Cancer biotech company Nuvalent has announced a $300 million public offering of its common stock following positive Phase I results for its ALK-selective tyrosine kinase inhibitor candidate, NVL-655, in ALK-positive non-small cell lung cancer patients, with a 39% objective response rate observed in evaluable patients.

Topics:businessbiotechpharmaceuticals#alk-selective-tyrosine-kinase-inhibitor#biotechpharmaceuticals#cancer-biotech#non-small-cell-lung-cancer#nuvalent#public-offering
Share this article
  1. Nuvalent's $300M offering; Spark ends epilepsy deal; A small IPO  Endpoints News
  2. Nuvalent Announces Public Offering of Common Stock  Yahoo Finance
  3. View Full Coverage on Google News

Want the full story? Read the original reporting

Read on Endpoints News